A STUDY ON DEVELOPING ISOCONAZOLE PRONIOSOMAL GEL TO TREAT FUNGAL INFECTION
Keywords:
proniosomal gel, isoconazoleAbstract
Antifungal medicines treat fungal infections. Fungus in the soil, air and on your skin can cause yeast infections, ringworm, and nail and skin infections. Breathing in fungal spores can lead to respiratory illnesses. People who have weak immune systems are more prone to fungal infections that require antifungal medicine. Fungi grow as yeasts, molds or a combination of both. They reproduce through very tiny spores. These spores can exist in soil or become airborne. Proniosomal gel basically is a compact semi-solid liquid crystalline (gel) composed of non-ionic surfactants easily formed on dissolving the surfactant in a minimal amount of acceptable solvent and the least amount of aqueous phase and phosphate buffer. Proniosomal gels are typically present in transparent, translucent, or white semisolid gel texture, which makes them physically stable throughout storage and transport. This research work attempted to develop an isoconazole proniosomal gel to treat fungal infection. The research aimed to study the morphological shape and size of the developed drug to understand its effectiveness.
References
A. Garg, G. S. Sharma, A. K. Goyal, G. Ghosh, S. C. Si, and G. Rath, “Recent advances in topical carriers of anti-fungal agents,” Heliyon, vol. 6, no. 8, p. e04663, 2020, doi: 10.1016/j.heliyon.2020.e04663.
N. Kaur, A. Bains, R. Kaushik, S. B. Dhull, F. Melinda, and P. Chawla, “A review on antifungal efficiency of plant extracts entrenched polysaccharide‐based nanohydrogels,” Nutrients, vol. 13, no. 6, pp. 1–26, 2021, doi: 10.3390/nu13062055.
P. K. Bolla et al., “Clotrimazole loaded ufosomes for topical delivery: Formulation development and in-vitro studies,” Molecules, vol. 24, no. 17, 2019, doi: 10.3390/molecules24173139.
A. S. M. Abu El-Enin, M. K. A. Khalifa, A. M. Dawaba, and H. M. Dawaba, “Proniosomal gel-mediated topical delivery of fluconazole: Development, in vitro characterization, and microbiological evaluation,” J. Adv. Pharm. Technol. Res., vol. 10, no. 1, pp. 20–26, 2019, doi: 10.4103/japtr.JAPTR-332-18.
G. A. El-Emam, G. N. S. Girgis, M. M. A. El Sokkary, O. A. El-Azeem Soliman, and A. E. G. H. Abd El Gawad, “Ocular inserts of voriconazole-loaded proniosomal gels: Formulation, evaluation and microbiological studies,” Int. J. Nanomedicine, vol. 15, pp. 7825–7840, 2020, doi: 10.2147/IJN.S268208.
B. Havlickova and M. Friedrich, “The advantages of topical combination therapy in the treatment of inflammatory dermatomycoses,” Mycoses, vol. 51, no. SUPPL.4, pp. 16–26, 2008, doi: 10.1111/j.1439-0507.2008.01615.x.
P. M. Kasar, K. Kale, and D. G. Phadtare, “Formulation and Evaluation of Topical Antifungal Gel Containing Itraconazole,” Int. J. Curr. Pharm. Res., vol. 10, no. 4, p. 71, 2018, doi: 10.22159/ijcpr.2018v10i4.28470.
B. D. Thimmaraju R, A. Nasir Kurnool, T. D. R α, and A. Nasir Kurnool σ, “Proniosomal Gel: Formulation and Charecterization of an Antifungal Drug (Butenafine Hcl) Loaded Proniosomes for Topical Delivery,” Toxicol. Med., vol. 20, no. 5, 2020.
